CSL Behring, a subsidiary of Australian multinational pharmaceutical giant CSL, is reattempting to receive reimbursement benefits for its hemophilia treatment in Korea.

CSL Behring holds the domestic marketing authorization and reimbursement rights for the hemophilia drug Afstyla Inj which was developed by SK Chemicals.

According to industry sources on the 7th, the reimbursement adequacy of CSL Behring’s hemophilia B treatment ‘Idelvion Inj’ was discussed at the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee meeting that was held on the 7th.

The drug had previously been reviewed by the committee in July 2021. At the time, the